Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AN1-type zinc finger protein 3 (ZFAND3) is a nuclear DNA-binding protein and transcription factor that contains both A20 and AN1 zinc finger domains[1][3]. ZFAND3 acts within a nuclear protein complex to activate the transcription of invasion-related genes, including those involved in cell adhesion and migration, making it a crucial driver of glioblastoma invasion and possibly other invasive cancers[1][3][4]. It is also physiologically expressed in reproductive tissues where it contributes to germ cell maturation[2]. In cancer biology, ZFAND3 overexpression enhances the motility and invasiveness of glioblastoma cells, while knockout or downregulation impairs tumor infiltration into neighboring tissue[1][3][4]. ZFAND3 regulates the promoters of several key genes such as COL6A2, FN1, and NRCAM and interacts with various nuclear proteins, emphasizing its role as a transcriptional regulator rather than a traditional therapeutic drug target[1][3][4]. There are currently no drugs known to directly target ZFAND3, and it is not considered a typical therapeutic target class like a receptor or enzyme[7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on AN1-type zinc finger protein 3 (ZFAND3).